-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Publicat 2025Matèries: -
9
Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Publicat 2025Matèries: -
10
-
11
Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Publicat 2025Matèries: -
12
Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Publicat 2025Matèries: -
13
Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Publicat 2025Matèries: -
14
Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Publicat 2025Matèries: -
15
-
16
-
17
-
18
-
19
Tissue-specific analysis of RVA RNA levels (G5P[7], G9P[13]) in extraintestinal tissues.
Publicat 2025Matèries: -
20